See how the liar lies.
"He also said that we generated the antibody to their target which was the very, very hard, hardest self-antigen target to generate antibodies for.
The actual statement was that PPHM gave AVN "their" hardest target and from their experience, it was a "difficult antibody to develope." The LIAR implies that AVN technology has just done something that nobody else can do with THE HARDEST SELF ANTIGEN TARGET KNOWN TO MANKIND.
As Czeco98 pointed out this morning, the LIAR constantly posts here "claiming unproven potentials as facts." (not to mention outright lies too)
All info verifiable on PPHM website.
The LIAR whore strkes again.
"the very, very hard, hardest self-antigen target to generate antibodies for."
Legere did not say this. WHY do you insist on making shit up. You're just a despicable slut. Anything to pump a few more pennies out of this stock.
Your last line was interesting. -- He said that they can patent the antibody by means of identifying the epitopes. --
Do you or anyone else have a little more info on what is involved in patenting an Ab? ie. can there be separate patents given to 2 different Abs to same protein as long as they bind different epitopes?
Now, although I do own a few shares of Medarex, it is not enough to make any big difference to my portfolio. That said, PPHM's Mr. Legere said that they would be taking a look at ABGX and MEDX in the future. When he said muddy, he was referring to patents, and mostly in respect to CAT. He said that MEDX and ABGX had cross-licensing. He said that Avanir was the least expensive system to use, because we have clear and clean patents and no stacking on of royalties. He also said that we generated the antibody to their target which was the very, very hard, hardest self-antigen target to generate antibodies for. He further said that our technology was rapid and robust, and that we would be moving ahead with the other two targets for them quickly, which would be easy. He said that they can patent the antibody by means of identifying the epitopes.